Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Your provider will guide your specific dosing schedule
Further ongoing studies combining GLP-1 RAs with other therapies, such as resmetirom, hold great potential for optimizing treatment strategies for MASH-related fibrosis
Clinical trials have demonstrated that semaglutide is associated with reduced appetite and decreased food intake for many patients
The elements preventing us from building a GLP-1 offering pricing, availability of the active ingredients, confidence in the quality of the compounded versions of the drugs have evolved significantly over the last year and, given our success over the last few quarters, we have found a way to mitigate those challenges on the behalf of our customers
What sets IV therapy apart is the ability to customize your treatment
